Peptides are gaining traction for several key reasons: Specificity and targeting Unlike some medications that have broad, systemic effects (and consequently, systemic side effects), peptides are highly specific
It is also essential to know that because of these effects, people can tend to regain the weight that was lost after receiving treatment
So, Im definitely excited
In SOUL, composite HF endpoints were analysed as a secondary outcome, with oral semaglutide resulting in a non-significant reduction in HF events
Additionally, in EPP, where patients experience sensitivity to visible light due to the accumulation of the photosensitizer protoporphyrin IX, melanotan 1 has shown promise in increasing skin melanin density, leading to increased tolerance to photoprovocation and reduced skin pain
The critical gap is the absence of controlled studies testing the two together, so any conclusion about combined effects remains speculative as of 2026